Table 2.
LVEF ≥50% (N = 468, 13%) | LVEF 40–49% (N = 1482, 41%) | LVEF 30–39% (N = 1357, 38%) | LVEF <30% (N = 290, 8%) | |
---|---|---|---|---|
Historical medications | ||||
Aspirin | 46 (10%) | 127 (9%) | 156 (12%) | 42 (15%) |
Statin | 45 (10%) | 126 (9%) | 153 (11%) | 44 (15%) |
Beta‐blocker | 48 (10%) | 159 (11%) | 193 (14%) | 51 (18%) |
ACE inhibitor/ARB | 45 (10%) | 147 (9%) | 188 (14%) | 54 (19%) |
Aldosterone receptor antagonist | 1 (<1%) | 9 (1%) | 5 (<1%) | 3 (1%) |
Medications on arrival | ||||
Aspirin | 466 (>99%) | 1476 (>99%) | 1353 (>99%) | 288 (99.3%) |
Statin | 466 (>99%) | 1476 (>99%) | 1352 (>99%) | 287 (99%) |
P2Y12 inhibitor | 468 (100%) | 1474 (>99%) | 1352 (>99%) | 288 (99%) |
Beta‐blocker | 115 (25%) | 294 (20%) | 235 (17%) | 25 (9%) |
Anticoagulant | 305 (65%) | 1038 (70%) | 914 (67%) | 110 (38%) |
Discharge medications, n (%) 1 | ||||
Aspirin | 455 (100%) | 1432 (>99%) | 1275 (>99%) | 221 (100%) |
Statin | 453 (>99%) | 1429 (>99%) | 1266 (99%) | 221 (100%) |
P2Y12 inhibitor | 452 (99%) | 1426 (>99%) | 1273 (>99%) | 217 (98%) |
Beta‐blocker | 444 (98%) | 1417 (99%) | 1252 (98%) | 216 (98%) |
ACE inhibitor/ARB | 363 (80%) | 1164 (81%) | 1250 (98%) | 215 (97%) |
Aldosterone receptor antagonist | 97 (21%) | 359 (25%) | 883 (69%) | 146 (68%) |
Guideline‐directed medical therapies at 1 year (missing = 310, 10%), n (%) 2 | ||||
Aspirin | 334 (85%) | 1076 (87%) | 917 (85%) | 156 (87%) |
P2Y12 inhibitor | 282 (72%) | 805 (65%) | 774 (72%) | 118 (66%) |
Statin | 308 (79%) | 991 (80%) | 868 (80%) | 149 (83%) |
Beta‐blocker | 309 (79%) | 989 (80%) | 843 (78%) | 142 (79%) |
ACE inhibitor/ARB | 183 (47%) | 570 (46%) | 451 (42%) | 91 (51%) |
Aldosterone receptor antagonist | 19 (5%) | 65 (5%) | 61 (6%) | 10 (6%) |
Sacubitril/valsartan | 15 (4%) | 42 (3%) | 35 (3%) | 6 (3%) |
Of those surviving to discharge.
Of those surviving to 1 year.